OncoRedox

Company Overview

Snapshot

Founded in August 2022, OncoRedox operates with 1–10 employees. The company has raised $890,000 across one funding round from one investor. In February 2023, OncoRedox secured Seed funding from Peregrine Ventures.

Business overview

OncoRedox is a Health Tech & Life Sciences company developing a point-of-care testing device for cancer detection. The company's core technology utilizes 'Redox-omics' analysis of urine samples, employing biochemical electrodes to detect redox metabolic signatures, which are then analyzed using an AI model. OncoRedox operates within the medical devices sector, specifically focusing on diagnostics devices, and serves the healthcare market, targeting providers.

Company Intelligence Q&A

What is OncoRedox's core technology?

OncoRedox's core technology is based on 'Redox-omics' analysis of urine samples, utilizing biochemical electrodes to detect redox metabolic signatures, which are then processed with an AI analysis model for cancer detection.

When was OncoRedox founded?

OncoRedox was founded in August 2022.

Which investor participated in OncoRedox's Seed round?

In February 2023, OncoRedox secured Seed funding from Peregrine Ventures, which was the sole investor in the round.

What is the primary sector OncoRedox operates in?

OncoRedox operates primarily in the Health Tech & Life Sciences sector, with a focus on Medical Devices and Diagnostics Devices.

What is OncoRedox's product stage?

OncoRedox's product is currently in the R&D stage, focusing on the development of a point-of-care testing device for cancer detection.